• 6906 Citations
  • 36 h-Index
1987 …2024
If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Professor Howard Gurney is the Director of Clinical Trials for the Faculty of Medicine and Health Sciences at Macquarie University. 

Professor Gurney has a firm background in clinical research and has subspecialty interests in urogenital cancers including prostate, bladder, testis and kidney cancer. 

He has been the principal investigator for over 100 clinical trials and has published over 100 peer-reviewed articles in journals and book chapters.  Current research interests include the pharmacogenomics and therapeutic monitoring of chemotherapy and targeted therapies and he has published widely in this area.  He is regarded as a leading authority on mechanisms for safe dosing of anticancer agents and has held research grants and has written a number of invited editorials on these topics. 

Fingerprint Dive into the research topics where Howard Gurney is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 6 Similar Profiles
Prostatic Neoplasms Medicine & Life Sciences
Renal Cell Carcinoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Castration Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Survival Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2013 2024

Research Outputs 1987 2019

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Rini, B. I., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Suarez, C., Bracarda, S., Stadler, W. M., Donskov, F., Lee, J. L., Hawkins, R., Ravaud, A., Alekseev, B., Staehler, M., Uemura, M., De Giorgi, U., Mellado, B., Porta, C., Melichar, B., Gurney, H. & 12 othersBedke, J., Choueiri, T. K., Parnis, F., Khaznadar, T., Thobhani, A., Li, S., Piault-Louis, E., Frantz, G., Huseni, M., Schiff, C., Green, M. C. & Motzer, R. J., 15 Jun 2019, In : The Lancet. 393, 10189, p. 2404-2415 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Renal Cell Carcinoma
Randomized Controlled Trials
Disease-Free Survival
Ligands
Research Personnel

Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma

Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., Lee, J. L., Vasiliev, A., Miller, W. H., Gurney, H., Schmidinger, M., Larkin, J., Atkins, M. B., Bedke, J., Alekseev, B., Wang, J. & 8 othersMariani, M., Robbins, P. B., Chudnovsky, A., Fowst, C., Hariharan, S., Huang, B., Di Pietro, A. & Choueiri, T. K., 21 Mar 2019, In : New England Journal of Medicine. 380, 12, p. 1103-1115 13 p.

Research output: Contribution to journalArticleResearchpeer-review

Renal Cell Carcinoma
Disease-Free Survival
sunitinib
avelumab
axitinib
Plasmas
Monitoring
Neoplasms
Drug Monitoring
Castration

Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer

Al-Mansouri, L. & Gurney, H., 16 Jul 2019, In : Asia-Pacific Journal of Clinical Oncology. 8 p.

Research output: Contribution to journalReview articleResearchpeer-review

Castration
Prostatic Neoplasms
docetaxel
Drug Therapy
Taxoids

Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?

Al-Mansouri, L., Arasaratnam, M. & Gurney, H., 14 Jun 2019, In : European Journal of Hospital Pharmacy.

Research output: Contribution to journalArticleResearchpeer-review

Prostatic Neoplasms
Survival
Prostate-Specific Antigen
Castration
Alkaline Phosphatase